ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADMS Adamas Pharmaceuticals Inc

8.22
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adamas Pharmaceuticals Inc NASDAQ:ADMS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.22 9.33 8.30 0 01:00:00

Adamas to Present at Upcoming BAML Investor Conference

13/05/2019 4:14pm

GlobeNewswire Inc.


Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Adamas Pharmaceuticals Charts.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief Executive, is scheduled to present at the following investor conference:

  • Bank of America Merrill Lynch (BAML) 2019 Health Care Conference on Wednesday, May 15 at 1:40 p.m. EDT (10:40 a.m. PDT)

The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:

Investors: Peter VozzoManaging Director, Westwicke443-213-0505peter.vozzo@westwicke.com

Media: Sarah MathiesonVice President of Corporate Communications510-450-3528smathieson@adamaspharma.com

1 Year Adamas Pharmaceuticals Chart

1 Year Adamas Pharmaceuticals Chart

1 Month Adamas Pharmaceuticals Chart

1 Month Adamas Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock